Olaparib Plus Abiraterone Produces Longest Median OS to Date in First-Line mCRPC Setting
Adding olaparib to first-line treatment with abiraterone extends overall survival in patients with metastatic castration-resistant prostate cancer, a phase 3 study suggests.